High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML -Commentary Mike P Wattjes and Clemens Warnke
Expert panel guidelines established by the magnetic resonance imaging in multiple sclerosis (MAGN-IMS) collaboration (http://www.magnims.eu) and an UK-Ireland initiative stressed the importance of a standardized pharmacovigilance strategy for natalizumab-treated patients with multiple sclerosis (MS). Although there were differences with respect to the progressive multifocal leukoencephalopathy (PML) risk classification, both guidelines agreed on the use of high-frequency brain magnetic resonance imaging (MRI) scanning (every 3-4 months) in patients being at higher risk of developing PML. 1,2 These recommendations have subsequently been incorporated into the natalizumab label update by the European Medicines Agency (EMA). 3 Without any doubt, such recommendations create extra costs, take limited imaging resources, and may pose unnecessary burden to the patients. Are they sufficiently supported by class I evidence? Are they based on a solid cost-benefit analysis? The answer is: NO. Anecdotal evidence only suggests that strict MRI pharmacovigilance using brain MRI may lead to an earlier detection of PML (preferably at a pre-/ asymptomatic stage) and may associate with a better functional outcome following PML. 4 A suggested abbreviated brain MRI protocol including fluidattenuated inversion recovery (FLAIR), T2-weighted imaging, and diffusion-weighted imaging (DWI) has never prospectively been validated for these purposes. A substantial number of small asymptomatic PML lesions may be undetectable on DWI, 5 and the proposed scanning interval of 3-4 months is based on class IV evidence. Additionally, the potential challenges in interpretation of brain MRI in particular with respect to lesion differentiation (e.g. MS vs PML) are quite obvious [6] [7] [8] as also nicely elaborated in the position statement of Dr Enzinger. ("High frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML." "NO.") So, should we then generally omit the MRI screening in patients at high risk of PML? The answer is once again: NO. Fortunately, PML, although increasingly reported and recognized in therapy-induced immunosuppression, still is a rare disease. 9 It is almost impossible to provide class I evidence for a rare disease in a heterogeneous group of patients. As such, in the absence of evidence, expert opinions that guide clinicians and help to standardize patient care can be a valuable alternative. Absence of solid data does not call for omission of obtaining such data. Indeed, standardized protocols may help to move the field forward, allowing for more reliable interpretation of MRI in the context of suspicion of PML in the future, and the search for added diagnostic tools to earlier facilitate the diagnosis of PML. 10 Technical solutions such as a web-based MRI second opinion reporting platform providing easy access to a world-wide expert opinions may be developed, and help physicians reading and interpreting MRI scans (http://www.ixico. com/digital-health), possibly in the future even outside of diagnosing natalizumab-associated PML.
Overall, will MRI screening in patients at high risk of PML be feasible and should we perform it? We believe: YES. Although it is unclear to date how many patients are needed to be screened by MRI before preventing a single symptomatic case, or preventing severe sequelae of clinically manifest PML, drug development outruns this controversy and makes the YES practically MP Wattjes and C Warnke feasible. With a growing armamentarium of therapeutic alternatives, a drug that carries a risk of 1% or higher for a potentially life-threatening complication such as PML needs to be carefully weighed with the individual benefits. 11 In consequence, carefully counseling the patients will often lead to alternative treatment decisions and reducing the number of patients at this specific risk that requires screening protocols for PML. Nonetheless, this will not diminish the need for educating physicians, nurses, and patients in drug-specific pharmacovigilance strategies. Any new drug that proves highly effective in MS will accompany with substance-specific adverse events. Thus, this discussion leads beyond, and calls for a health care system that supports the time invested by independent physicians and researchers seeking the best outcome for patients, and spending time on developing novel strategies to mitigate and combat treatment-associated risks. 12
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